Travere Therapeutics, Inc. (TVTX) — 10-Q Filings

10-Q Filings (6)

• Travere Therapeutics Swings to Profit on Soaring FILSPARI Sales — Oct 30, 2025 Risk: medium
  Travere Therapeutics, Inc. (TVTX) reported a significant turnaround, achieving net income of $25.7 million for the three months ended September 30, 2025, compar
• Travere Therapeutics Posts Strong Q2 Revenue Growth, Up 5.5% — Aug 6, 2025 Risk: medium
  Travere Therapeutics, Inc. reported total revenues of $366 million for the three months ended June 30, 2025, a significant increase from $347 million in the sam
• Travere Therapeutics Q1 2025 10-Q Filed — May 1, 2025 Risk: medium
  Travere Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including revenue from product sales a
• Travere Therapeutics Files Q3 2024 10-Q — Oct 31, 2024 Risk: medium
  Travere Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Retrophin, Inc., reported financial results for
• Travere Therapeutics Files Q2 2024 10-Q — Aug 1, 2024 Risk: medium
  Travere Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its clinical trial
• Travere Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk:
  Travere Therapeutics, Inc. (TVTX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Travere Therapeutics reported financial results for the quarter e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX